A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
The present disclosure provides pharmaceutical compositions comprising i) a MsP1 enzyme and ii) one or more pharmaceutically acceptable carriers. The disclosure also provides methods comprising the pharmaceutical compositions for use in treating patients with various disease states, as well as related sequences and expression vectors.
The subject invention pertains to design of strategies that enable the more effective utilization of active intercalation materials in the production of lithium ion batteries. Na- and K-ion intercalation "props" open the ID tunnel, reduces electrostatic repulsions between inserted Li-ions, and entirely modifies diffusion pathways, enabling orders of magnitude higher Li-ion diffusivities and accessing higher capacities. The subject invention provides materials and batteries comprising the materials produced via the methods disclosed within this application.
4.
CONVERSION OF CARBON DIOXIDE TO HIGHER VALUE CHEMICALS
Escherichia coli Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). The high thermostability and high microbial expression yield make DARPin an attractive alternative to antibody therapeutics. The present disclosure provides monomer proteins, dimer proteins, and trimer proteins, as well as pharmaceutical compositions and methods utilizing the same.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
Compact and affordable microscopes for ultraviolet microscopy, in particular in the deep ultraviolet region, can be constructed using narrowband ultraviolet light sources such as, e.g., ultraviolet LEDs, ultraviolet-transmissive lenses made from fused silica or quartz, and ultraviolet- sensitive detectors. Suitable detectors include CCD or CMOS sensors without ultraviolet-blocking layers, a fluorescent screen imaged by a visible-light camera, photographic paper, or cyanotype-coated paper.
G01J 3/36 - Mesure de l'intensité des raies spectrales directement sur le spectre lui-même Étude de plusieurs bandes d’un spectre à l’aide de détecteurs distincts
G01N 21/33 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
Improvements to aspects of magnet gear systems are disclosed. In various aspects, a support system for rotors includes bearing supports to maintain an air gap between adjacent rotors. In various aspects, a modular system for creating magnetic poles using a single magnet. In various aspects, an eccentric rotor design uses a flux shield to reduce losses to improve performance of the magnetic gear system. In various aspects, a multi-stage magnetic gear systems include combinations of axial and/or radial flux rotor designs. In various aspects, a back iron design includes contoured features designed to retain magnets in a press-fit arrangement.
H02K 21/22 - Moteurs synchrones à aimants permanents; Génératrices synchrones à aimants permanents avec des induits fixes et des aimants tournants avec des aimants tournant autour des induits, p.ex. volants magnétiques
H02K 1/27 - Noyaux rotoriques à aimants permanents
H02K 21/14 - Moteurs synchrones à aimants permanents; Génératrices synchrones à aimants permanents avec des induits fixes et des aimants tournants avec des aimants tournant à l'intérieur des induits
H02K 21/24 - Moteurs synchrones à aimants permanents; Génératrices synchrones à aimants permanents avec des induits fixes et des aimants tournants avec des aimants disposés axialement en face des induits, p.ex. dynamos de bicyclette du type moyeu
H02K 41/03 - Moteurs synchrones; Moteurs pas à pas; Moteurs à réluctance
F16C 39/06 - Allégement de la charge appliquée aux paliers par moyens magnétiques
G01R 33/038 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des aimants permanents, p.ex. des balances, des dispositifs à torsion
8.
TUBULAR STRUCTURES, METHODS, AND APPARATUSES FOR MAKING AND USING THE SAME
Tubular structures, apparatuses, and methods for making tubular structures are disclosed herein. Walls of the tubular structures can include a hydrogel. A luminal material extends through the tubular wall. A cell population can live in the luminal material, the tubular wall, and/or on an outer surface of a tubular structure. Apparatuses for making tubular structures can include one or more inner extrusion nozzles removably positioned coaxially within one or more outer extrusion nozzles. The outer extrusion nozzle can be removably or permanently positioned within a housing of the apparatus, positioned above a column-shaped container. Methods of making a tubular structure can include coextruding a wall solution and a luminal solution into the column-shaped container and polymerizing the wall solution into a tubular structure. In some aspects, a light source can be configured to illuminate a light-permeable wall of the container or the nozzles for the purpose of polymerizing the wall solution.
A61M 39/08 - Tubes; Moyens de rangement spécialement adaptés aux tubes
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Shah, Nikhil Dipak
Reddy, Narainsai K.
Yamada, Akira
Alias, Basil
Abrégé
A handle assembly for a gouge includes a handle, where a distal end of the handle includes first threads. The handle assembly includes a grip that has an interior channel. At least a portion of the interior channel includes second threads that mate with the first threads on the distal end of the handle to secure the grip to the handle. The handle assembly also includes a collet. A distal end of the collet includes an opening that is sized to receive a proximal end of a gouge. The handle assembly further includes a collar that is sized to receive the collet, and that mounts onto a distal end of the grip.
The present disclosure provides multiple anti-hCD20 mAbs as well as humanization of antibodies. The antibodies described herein are chicken-derived and exhibit significantly enhanced B-cell-specific antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) potency as well as improved depletion of B lymphoma cells in vivo relative to Rituximab.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Scherr, Jonathan
Head, Timothy
Haas, Derek
Shoemate, Jack
Tsvetkov, Pavel
Towell, Rusty
Abrégé
A molten salt reactor system includes a fuel salt system configured to circulate a molten salt through a reactor vessel. The molten salt reactor system further includes an inert gas system fluidically coupled with the fuel salt system and configured to maintain a pressurized volume fluidically between the molten salt and a drain tank by circulating an inert gas along a first inert flow path. The molten salt reactor system further includes an equalization system configured to equalize pressure between all head spaces of the molten salt reactor system including the reactor vessel and the drain tank in response to a shutdown event. The inert gas system is configured to cease maintenance of the pressurized volume in response to the shutdown event.
Embodiments of the disclosure include methods and compositions related to use of compound comprising a particular peptide linked to a dye. In specific embodiments, the peptide DIRG is linked to the BODIPY dye. In specific embodiments, the compositions are utilized for treatment of neurological conditions and secondary pathologies related therewith, such as spinal cord injury and Alzheimer's Disease, as examples.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
13.
DELOCALIZED LITHIUM ION FLUX BY SOLID-STATE ELECTROLYTE COMPOSITES COUPLED WITH 3D POROUS NANOSTRUCTURES FOR HIGHLY STABLE LITHIUM METAL BATTERIES
A lithium metal anode that reduces formation of lithium dendrites includes a porous carbon nanotube (CNT) electrode, a solid-state electrolyte (SE) composite layer disposed on the porous CNT electrode, and a polypropylene (PP) separator layer disposed on the SE composite layer. The SE composite layer induces uniform lithium growth, suppressing dendrite growth. The suppression of dendrite growth improves performance lithium-based designs and enables improved capacity retention.
H01M 4/133 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de matériau carboné, p.ex. composés d'intercalation du graphite ou CFx
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
14.
DECARBONIZATION BY SOLAR-ASSISTED TUNABLE CARBONHYDROGEN-OXYGEN INTEGRATION TO SOLID CARBON AND ENRICHED SYNGAS
QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (Qatar)
TEXAS A&M UNIVERSITY (USA)
Inventeur(s)
El-Halwagi, Mahmoud M.
Elbashir, Nimir O.
Sengupta, Debalina
Challiwala, Mohamedsufiyan A.
Choudhury, Hanif A.
Abrégé
A system includes an allocation control system configured to receive oxygen gas, methane gas, carbon dioxide gas, and steam, determine a proper ratio of the oxygen gas, the methane gas, the carbon dioxide gas, and the steam, and mix the oxygen gas, the methane gas, the carbon dioxide gas, and the steam according to the determined ratio to generate a mixture stream. The system further includes a syngas and carbon generator configured to: receive the mixture stream from the allocation control system, and generate syngas and solid carbon using the received mixture stream, wherein the syngas comprises hydrogen gas and carbon monoxide gas. The proper ratio of the oxygen gas, the methane gas, the carbon dioxide gas, and the steam is determined using an atomic tracking model based on a predetermined condition for the syngas and the solid carbon to be generated by the syngas and carbon generator.
C01B 3/02 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène
C01B 3/32 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p.ex. de l'eau, du gaz carbonique, de l'air
B01J 19/24 - Réacteurs fixes sans élément interne mobile
C01B 3/34 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p.ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants
15.
FABRICATED ENGINEERED SKIN DERMIS COMPOSITIONS AND METHODS THEREOF
The present disclosure provides an engineered dermis comprising one or more layers of human dermal fibroblast compositions as well as scaffolds and methods of the same. The disclosure also provides compositions comprising one or more interwoven extracellular matrices, wherein the interwoven extracellular matrices have been decellularized as well as scaffolds and methods of the same.
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (USA)
SAINT ANSELM COLLEGE (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Meek, Mariah
Mamoozadeh, Nadya
O'Leary, Shannon
Mahapatra, Nihar
Portnoy, David
Abrégé
Methods and systems for species identification are disclosed. The methods and systems include: obtaining first, second, and third trained artificial intelligence (AI) models; obtaining one or more runtime images including a subject; determining a first confidence level of a morphological group of the subject based on the first AI model; determining a second confidence level of a species of the subject based on the morphological group and the second AI model; in response to the second confidence level being lower than a predetermined confidence level; performing a genomic test for the subject based on the determined morphological group or the determined species of the subject; and identifying the species of the subject based on a test result of the genomic test based on the third AI model. Other aspects, embodiments, and features are also claimed and described.
G06V 10/77 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source
G06V 20/00 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène
G06F 18/21 - Conception ou mise en place de systèmes ou de techniques; Extraction de caractéristiques dans l'espace des caractéristiques; Séparation aveugle de sources
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes
The disclosed invention provides a hierarchically textured cement-based membrane exhibiting orthogonal wettability, specifically, superhydrophilic and underwater superoleophobic characteristics. In one embodiment, in situ formation of ettringite needles accompanied by embedding of solid impermeable structures such as cubes, cuboids, prisms, pyramids, platonic solids, torus, cone, cylinder, spheres or mixtures thereof, such as glass spheres, imbues micron- and nanoscale texturation to mesh membranes, such as stainless steel mesh membranes and provides for the separation of silt and oil from produced water at high flux rates (1600 L/h*m2). Oil concentration can be reduced as low as 1 ppb with an overall separation efficiency of 99.7% in single-pass filtration.
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétés; Procédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
A system for dry manufacturing an electrode for an energy storage device includes a substrate configured to move in a feed direction. In addition, the system includes a powder applicator configured to deposit a dry powder onto a surface of the substrate. Further, the system includes at least one pair of spreading rollers. The pair of spreading rollers includes an upper spreading roller and a lower spreading roller positioned below the upper spreading roller. The upper spreading roller and the lower spreading roller are positioned downstream of the powder applicator relative to the feed direction. Still further, the system includes at least one pair of compaction rollers.
H01M 4/13 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication
19.
BIOIMPEDANCE RING SENSOR FOR PHYSIOLOGICAL MONITORING
A bioimpedance ring sensor configured to be worn on a finger of a human subject. The bioimpedance ring sensor may include a ring-shaped body having a central axis, a radially inner annular surface, and a radially outer annular surface. The bioimpedance ring sensor may also include a plurality of electrodes positioned on the radially inner annular surface. The plurality of electrodes may include injection electrodes and sensing electrodes. The bioimpedance ring sensor may also comprise a controller coupled to the plurality of electrodes. The controller may be configured to direct an electric current to at least one of the injection electrodes, to detect a voltage potential via at least one of the of sensing electrodes, and to determine bioimpedance associated with the human subject based upon the electric current and the voltage potential.
in situviaIrpex lacteusIrpex lacteus, and can promote PFAS detoxification. RAPIMER arises from cheap lignocellulosic sources, enabling a broader impact on sustainability and a new means for low-cost pollutant remediation.
C02F 1/58 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par élimination de composés spécifiés dissous
C02F 3/32 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout caractérisé par les animaux ou végétaux utilisés, p.ex. les algues
A62D 3/02 - Procédés pour rendre les substances chimiques nuisibles inoffensives ou moins nuisibles en effectuant un changement chimique dans les substances par des procédés biologiques, c. à d. des procédés utilisant des enzymes ou des micro-organismes
D21C 9/18 - Post-traitement de la pâte de cellulose, p.ex. de la pâte de bois, ou des linters de coton Élimination de l'eau
B09C 1/10 - Régénération de sols pollués par des procédés microbiologiques ou utilisant des enzymes
C09K 3/32 - Substances non couvertes ailleurs pour traiter les polluants liquides, p.ex. le pétrole, l'essence ou les corps gras
D01D 5/40 - Formation des filaments, fils ou similaires par application à la dispersion ou à la solution de polymères destinée à former les filaments d'une force de cisaillement, p.ex. par agitation
21.
METHOD FOR CREATING CRUDE OIL SYNTHESIZED FLUID HAVING SURFACTANT AND DEMULSIFICATION PROPERTIES
A high voltage discharge generating a plasma wave front is disposed within a headspace over an oil-containing liquid in order to create various chemical changes within the headspace, and ultimately within the liquid in order to inactivate various microbes, synthesize new chemicals, speed separation of a mixture, and aid in oil extraction. Such a discharge may be repeated at an optimum duration and duty-cycle to maximize the chemical effects of the non-equilibrium plasma at a substantially lower temperature than for an equilibrium plasma.
B01D 17/05 - Rupture d'émulsions par traitement chimique
C10G 33/04 - Déshydratation ou désémulsification des huiles d'hydrocarbures par des moyens chimiques
C10G 15/08 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques par des moyens électriques ou par des vibrations électromagnétiques ou mécaniques
Technologies for dual-stage charge collection and energy storage include an energy storage module having a first stage energy storage device, a second stage energy storage device, and a microcontroller. The first stage energy storage device may include capacitive storage and the second stage energy storage device may include battery storage. When rectified input power is available from an unbalanced peak alternating current power signal, the microcontroller activates quick charging of the first stage energy storage device. When the first stage energy storage device is full, the microcontroller activates charging of the second stage energy storage device. When the second stage energy storage device is full, the microcontroller activates power delivery to an external load. Other embodiments are described and claimed.
B60L 58/16 - Procédés ou agencements de circuits pour surveiller ou commander des batteries ou des piles à combustible, spécialement adaptés pour des véhicules électriques pour la surveillance et la commande des batteries en fonction du vieillissement de la batterie, p.ex. du nombre de cycles de charge ou de l'état de santé [SoH]
B60L 58/18 - Procédés ou agencements de circuits pour surveiller ou commander des batteries ou des piles à combustible, spécialement adaptés pour des véhicules électriques pour la surveillance et la commande des batteries de plusieurs modules de batterie
G01R 31/392 - Détermination du vieillissement ou de la dégradation de la batterie, p.ex. état de santé
23.
TECHNOLOGIES FOR ENERGY GENERATING MULTILAYER COMPOSITE MATERIAL FOR PAD APPLICATION IN TRANSPORTATION SYSTEMS
A multilayer composite energy generation device includes a bottom layer grouping including a fabric layer coated with a hydrophobic adhesive material, a middle layer including one or more piezoelectric transducers, and an upper layer include one or more fabric layers coated with a hydrophobic adhesive material. The middle layer may also be coated with a hydrophobic adhesive material. The piezoelectric transducer may include a thin-film piezoelectric material such as lead zirconium titanate (PZT). The hydrophobic adhesive material may be a paint-like polymeric material. The energy generation device may be coupled to a pavement segment such as a bicycle path, pedestrian path, or roadway.
E01F 11/00 - Bourrelets ou autres dispositifs sensibles encastrés dans les pavés ou autres revêtements routiers
F03G 7/00 - Mécanismes produisant une puissance mécanique, non prévus ailleurs ou utilisant une source d'énergie non prévue ailleurs
F03G 7/08 - Mécanismes produisant une puissance mécanique, non prévus ailleurs ou utilisant une source d'énergie non prévue ailleurs récupérant l'énergie produite par le balancement, le roulement, le tangage ou des mouvements semblabes, p.ex. par les vibrations d'une machine
H10N 30/00 - Dispositifs piézo-électriques ou électrostrictifs
H10N 30/30 - Dispositifs piézo-électriques ou électrostrictifs à entrée mécanique et sortie électrique, p.ex. fonctionnant comme générateurs ou comme capteurs
F03G 7/04 - Mécanismes produisant une puissance mécanique, non prévus ailleurs ou utilisant une source d'énergie non prévue ailleurs utilisant les différences de pression ou les différences thermiques existant dans la nature
Provided herein are nanoengineered biomaterial inks used to 3D print a biocompatible, flexible electronic device, for example, a hydrogel constructs a biocompatible, flexible electronic device or 3D printed wearable electronic devices. The biocompatible, flexible electronic device may be a crosslinked gelatin-SH-2D-MoS2 nanoassembly. Also provided are methods for nanoengineering a biomaterial ink and for determining a treatment for a subject in need thereof utilizing the biocompatible, flexible electronic device.
C08L 5/00 - Compositions contenant des polysaccharides ou leurs dérivés non prévus dans les groupes ou
C08K 3/30 - Composés contenant du soufre, du sélénium ou du tellure
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p.ex. de buses de jet
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
B33Y 70/10 - Composites de différents types de matériaux, p.ex. mélanges de céramiques et de polymères ou mélanges de métaux et de biomatériaux
25.
BI-DIRECTIONAL BLOOD PUMPS AND ONE-WAY FILTER TRAPS AND SYSTEMS INCLUDING THE SAME
A blood pump system switchable between a first flow direction and a second flow direction includes a filter trap and a blood pump. The blood pump has an impeller configured to rotate at a predetermined speed in a first rotary direction to generate fluid flow in the first flow direction at a first pressure and a first flowrate. The impeller is configured to rotate in a second rotary direction at the predetermined pump speed to generate fluid flow in the second flow direction at a second pressure and a second flowrate. The first flowrate and the first pressure are different from the second flowrate and the second pressure with the impeller operating at the predetermined pump speed. The filter trap includes a one-way valve configured to remain closed with fluid flow the first direction and to open with fluid flow in the second direction.
A61M 60/237 - Pompes pour le sang à déplacement non positif comportant un élément rotatif agissant sur le sang, p.ex. un impulseur le flux de sang à travers l’élément rotatif ayant des composants principalement axiaux, p.ex. pompes à écoulement axial
A61M 60/122 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient
A61M 60/148 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables par, dans, à l’intérieur, en ligne, se ramifiant dans ou autour d’un vaisseau sanguin en ligne avec un vaisseau sanguin par résection ou techniques analogues, p.ex. dispositifs permanents d’assistance cardiaque endovasculaire
A61M 60/174 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables dans ou sur le cœur, ou autour du cœur à l’intérieur d’un ventricule, p.ex. pompes à ballon intra-ventriculaires refoulant le sang vers le ventricule ou le système artériel par une canule interne au ventricule ou au système artériel
A61M 60/30 - Leurs finalités médicales étant autres que l’amélioration du débit cardiaque
A cryogenic testing apparatus includes a housing in which a cryogenic chamber is positioned. An upper channel is arranged around the cryogenic chamber and is configured to receive a cryogen. A lower channel is arranged below the upper channel and is configured to receive cryogen from the upper channel. As the cryogen flows through the cryogenic testing apparatus, the cryogen contacts an exterior of the cryogenic chamber. The cryogenic chamber is unsealed and is configured to receive a gas to create positive pressure within the cryogenic chamber.
G01N 3/18 - Exécution de tests à des températures élevées ou basses
G01N 19/02 - Mesure du coefficient de frottement entre matériaux
G01N 3/08 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique par application d'efforts permanents de traction ou de compression
27.
SCALABLE SYNTHESIS OF HETEROATOM-DOPED CARBON NANOTUBES FOR ELECTROCHEMICAL CARBON DIOXIDE REDUCTION
Heteroatom-doped carbon nanotubes, catalytic electrodes, reactors, methods of making heteroatom-doped carbon nanotubes, and methods of reducing a molecule are described. In an embodiment, the hetero atom-doped carbon nanotube comprises single atomic metal-nitrogen-carbon (M-N-C) sites for use aass aann electrocatalyst. In an embodiment, the heteroatom-doped carbon nanotube comprises single atomic Fe-N bonds as active sites configured to convert carbon dioxide to carbon monoxide. In an embodiment, the active sites are disposed on an outer surface of the heteroatom-doped carbon nanotube. In an embodiment, the heteroatom-doped carbon nanotube further comprises Ni metal nanoparticles. In an embodiment, the Ni metal nanoparticles are disposed in joints of the heteroatom-doped carbon nanotube. In an embodiment, the Ni metal nanoparticles are encapsulated by graphitic carbon layers of the heteroatom-doped carbon nanotube.
In an embodiment, the present disclosure pertains to a multi-network hydrogel composed of a first network, a second network, and a third network. In some embodiments, the first network, the second network, and the third network form a poly(2-acrylamido-2-methylpropane sulfonic acid) (PAMPS)/A-isopropylacrylamide (NIPAAm) copolymerized with acrylamide (AAm)/poly((3- acylamidopropyl)trimethylammonium chloride) (PAMPS/P(NIPAAm-co-AAm)/PAPTAC) triple network hydrogel. In another embodiment, the present disclosure pertains to synthetic cartilage compositions composed of the multi-network hydrogels as disclosed herein. In a further embodiment, the present disclosure pertains to methods of forming the multi-network hydrogels of the present disclosure.
A high voltage discharge between two electrodes generating a plasma is disposed within a reactor chamber. Hydrocarbon gas and conductive liquid are passed over one or more electrodes, such that the conductive liquid cools the electrodes and avoids fouling. Such a discharge may result in hydrogen gas and additional carbon containing coproducts which may be used, released, or sequestered.
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage
C10G 15/08 - Craquage des huiles d'hydrocarbures par des moyens électriques, par des vibrations électromagnétiques ou mécaniques, par des radiations particulaires ou avec des gaz surchauffés dans des arcs électriques par des moyens électriques ou par des vibrations électromagnétiques ou mécaniques
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Hakim, Julie
Cosgriff-Hernandez, Elizabeth
Grunlan, Melissa
Abrégé
Embodiments of the disclosure concern devices comprised of resorbable, shape-memory foam configured to allow for healing at a desired location. In particular embodiments, use of the device at the location utilizes the inherent environment at the location to allow expansion of the device, resulting in an improved fit for the device. In specific cases, the device is a vaginal stent configured for use for pediatric or adolescent populations.
A61K 9/02 - Suppositoires; Bougies; Excipients pour suppositoires ou bougies
A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p.ex. les vaisseaux sanguins ou le cordon ombilical
A61F 6/22 - Obturateurs du canal déférent; Obturateurs des trompes de Fallope implantables dans le canal ou dans les oviductes
Technologies for optically controlling friction include a plasmon-active photofriction element, or a friction pixel. A structure includes a base substrate material, a plasmon-active element coupled to the base substrate material, and a frictional interface material. The frictional interface material is positioned at a surface of the structure and has a phonon mode. The plasmon-active element includes a pattern comprising multiple pattern elements that have a plasmon mode tuned to couple with the phonon mode of the frictional interface material. When illuminated, the plasmon mode of the plasmon-active element is excited. Thus, energy dissipation of a sliding contact across the surface of the structure is changed to generate an active decrease or increase in friction based on light illumination frequency or intensity. The frictional interface material may include silica, and the plasmon-active element may include graphene. Other embodiments are described and claimed.
G06F 3/0488 - Techniques d’interaction fondées sur les interfaces utilisateur graphiques [GUI] utilisant des caractéristiques spécifiques fournies par le périphérique d’entrée, p.ex. des fonctions commandées par la rotation d’une souris à deux capteurs, ou par la nature du périphérique d’entrée, p.ex. des gestes en fonction de la pression exer utilisant un écran tactile ou une tablette numérique, p.ex. entrée de commandes par des tracés gestuels
The present disclosure relates to compositions and methods for the treatment and/or prevention of SARS-CoV-2 infections. In one embodiment the method comprises the delivery of a pharmaceutical composition comprising a SARS-CoV-2 neutralizing synthetic protein, optionally wherein the protein is a trimeric protein composed of designed ankyrin repeat protein (DARPin) fused with a T4 foldon peptide that is administered non-invasively such as by nasal inhalation.
In an embodiment, the present disclosure pertains to a method of deposition of nanostructures with engineered patterns. In an additional embodiment, the present disclosure pertains to a method of preparing colloidal suspensions of hybrid nanoparticle systems (HNMS). In a further embodiment, the present disclosure pertains to a method of making a cellulose nanocrystal (CNC)-bonded carbon nanotube carbon fiber reinforced polymer (CNT-CFRP) hybrid composite. In another embodiment, the present disclosure pertains to a method of making a cellulose nanocrystal (CNC)-bonded graphene nanoplatelets (GNP) carbon fiber reinforced polymer (GNP-CFRP) hybrid composite. In a further embodiment, the present disclosure pertains to a method of making a hybrid cellulose nanocrystal (CNC)-graphene nanoplatelet(boron nitride nanobarb) (GNP-(BNNB))-carbon fiber (CF)Zpolyether ether ketone (PEEK) using spray-coating.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B01J 3/00 - Procédés utilisant une pression supérieure ou inférieure à la pression atmosphérique pour obtenir des modifications chimiques ou physiques de la matière; Appareils à cet effet
B82B 1/00 - Nanostructures formées par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p.ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
34.
CYANOBACTERIA CULTIVATION, SEDIMENTATION, AND UTILIZATION
The present invention is related to the fields of bioplastics. In particular, a strain of photosynthetic cyanobacteria (i.e. blue-green algae) having a high growth rate was engineered to overexpress limonene synthase. These engineered cyanobacteria improve auto-sedimentation for biomass harvest and provide for plastic bioremediation capture. Further, machine-learning methods are provided for improving some of the aspects of cultivating cyanobacteria including, but not limited to, assessing real-time light availability and predicting real-time algae growth rates to increase a cyanobacteria biomass.
In an embodiment, the present disclosure pertains to environmental biospecimen recovery after in-droplet gel encapsulation (eBRIDGE) platforms for co-culturing multiple microorganisms in gel microspheres and then transferring single-cell-derived clonal populations from within the gel microspheres into separate water-in-oil emulsion droplets for further processing and analysis. In some embodiments, the gel-encapsulated bacteria are released by lysing the gel matrix using an enzyme. The methods of the present disclosure provide a single workflow that goes from environmental microbial harvesting and amplification to functional interrogation of their characteristics.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12N 1/04 - Conservation des micro-organismes à l'état viable
CONTINUOUS AND RAPID PERPETUAL ELECTROSTATIC COALESCENCE PHASE SEPARATION AND DEMULSIFICATION OF OIL, WATER, AND SOLIDS USING PLASMA AT STANDARD CONDITIONS
Provided are systems and methods involving a plasma electro-coalescence reactor. The reactor includes a set of ports configured to receive an emulsified mixture into the reactor, receive a non-oxidative gas into the reactor, expel oil from the reactor, and expel water from the reactor. The reactor includes a set of electrodes including a first electrode in a headspace of the reactor, and a second electrode, the set of electrodes configured to receive a voltage at or in excess of a breakdown voltage of the non-oxidative gas.
In an embodiment, the present disclosure pertains to a method of reducing cytocidal activity of cells. In some embodiments, the method includes altering eukaryotic elongation factor- 2 kinase (eEF-2K) in a subject and inducing a reduction of cytocidal activity of cytotoxic T cells (CTLs) in the subject. In some embodiments, the altering of eEF-2K in the subject can include a decrease of eEF-2K in the subject.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61P 31/14 - Antiviraux pour le traitement des virus ARN
39.
INTERDIGITATED ELECTRODE-BASED DROPLET MANIPULATION IN MICROFLUIDIC SYSTEMS
In an embodiment, the present disclosure pertains to a droplet system, apparatus, or fluid sample testing system to accomplish high-precision and high-efficiency droplet manipulation (e.g., greater than 99% platform operation efficiency). In some embodiments, the droplet system, apparatus, or fluid sample testing system includes at least one microfluidic channel or chamber and at least one interdigitated electrode (IDE) that can create a localized electric field below and/or within at least one fluidic channel or chamber. In some embodiments, this allows size-specific and/or size-dependent droplet manipulation.
Systems and methods for automated separation and recovery of compounds from solution are disclosed herein. In some embodiments, the system can use a pump in fluid/air communication with a chromatography column to dissolve and recover astatine from a solution containing astatine, bismuth, and nitric acid. The system can be in communication with a controller that can automate and/or remotely signal each component of the system to execute the recovery without manual user inputs.
B01D 15/12 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
B01D 15/14 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à l'introduction de l'alimentation dans l'appareil
B01D 15/20 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives au conditionnement de la matière adsorbante ou absorbante
41.
WEARABLE PLASMONIC PAPERFLUIDICS FOR CONTINUOUS BIOFLUID ANALYSIS
In an embodiment, the present disclosure pertains to a wearable sensor. In some embodiments, the wearable sensor includes a double-sided adhesive layer, a paper microfluidic layer, and an encapsulation layer. In an additional embodiment, the present disclosure pertains to a method of biochemical analysis. In general, the method includes collecting biofluid from a subject via a wearable sensor and quantifying the biofluid. In some embodiments, the wearable sensor includes a double- sided adhesive layer and a paper microfluidic layer having a microfluidic channel in a serpentine configuration. In some embodiments the microfluidic channel includes an inlet to receive the biofluid, an outlet to collect the excess biofluid, and a plurality of plasmonic sensors.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
G01J 3/44 - Spectrométrie Raman; Spectrométrie par diffusion
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
In an embodiment, the present disclosure pertains to a supercapacitor composed of a cathode material, a gel electrolyte, and a zinc foil anode. In some embodiments, the cathode material, the gel electrolyte, and the zinc foil anode are in a multilayered configuration. In some embodiments, the cathode and anode materials provide load-bearing capability. In an additional embodiment, the present disclosure pertains to a method of making a supercapacitor. In general, the method includes fabricating a cathode material, preparing a gel electrolyte, coating a zinc foil electrode with the gel electrolyte, and sandwiching the zinc foil electrode with the cathode material. In some embodiments, the sandwiching forms a multilayered configuration composed of the cathode material, the gel electrolyte, and the zinc foil anode.
H01G 11/56 - Condensateurs hybrides, c. à d. ayant des électrodes positive et négative différentes; Condensateurs électriques à double couche [EDL]; Procédés de fabrication desdits condensateurs ou de leurs composants Électrolytes Électrolytes solides, p.ex. gels; Additifs pour ceux-ci
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 6/16 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments primaires; Leur fabrication Éléments avec électrolytes non aqueux avec électrolyte organique
H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p.ex. au magnésium ou à l'aluminium
43.
METHODS AND COMPOSITIONS TARGETING NUCLEUS ACCUMBENS-ASSOCIATED PROTEIN-1 FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS
Provided herein are methods of for enhancing or inducing an anti-tumor response or treating an autoimmune disorder by administering a therapeutically effective amount of an inhibitor of NAC 1. Also, provided herein are methods of enhancing effectiveness of a vaccine in a subject by administering to the subject a therapeutically effective amount of an inhibitor of NAC 1. Inhibitors of NAC1 can include a chemical agent, such as a composition containing NIC3, or a biological agent that inhibit the function of NAC1 protein, such as an isolated antibody or its binding fragment thereof that binds to NAC1. Inhibitors of NAC 1 can include a biological agent that reduces the expression of NAC1 gene, such as a NAC 1 -targeted siRNA administered as a nanoliposome or a CRISPR/Cas-based genome editing composition targeting the NAC1 Gene.
In an embodiment, the present disclosure pertains to a method of recycling that includes applying an electromagnetic field to a composite material having carbon fiber therein, heating the composition, degrading a matrix of the composite material, and recovering the carbon fiber from the composite material. In an additional embodiment, the present disclosure pertains to a method of non-contact recycling that includes applying an electromagnetic field to a composite material having carbon fiber therein with an electromagnetic applicator via at least one of direct current or alternating current, heating the composition, degrading a matrix of the composite material, and recovering the carbon fiber from the composite material. In some embodiments, the electromagnetic field is applied in a non-contact manner. In some embodiments, the heating is locally induced heating that includes increasing the temperature inside the composite material via an inside-out method thereby initiating pyrolysis within the composite material.
The present disclosure provides a vascular graft comprising i) one or more extracellular matrix compositions and ii) one or more hydrogels. In particular, the vascular grafts of the present disclosure can be functionalized and/or be completely biologic. The disclosure also provides methods of administering the vascular grafts as well as methods for forming the vascular grafts.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
In an embodiment, the present disclosure pertains to a stable formulation of a primary, secondary, and/or tertiary amino group containing composition that prevents or reduces formation of a nitroso impurity, or a method of making the stable formulation of a primary, secondary, and/or tertiary amino group containing composition. In some embodiments, the composition includes a drug having a primary, secondary, and/or tertiary amino group and a pharmaceutical excipient. In some embodiments, the pharmaceutical excipient is at least one of a protective pharmaceutical excipient or a non-protective pharmaceutical excipient. In some embodiments, the pharmaceutical excipient is processed with an organic solvent.
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide non condensés avec un autre cycle, p.ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
47.
STABLE PHARMACEUTICAL COMPOSITIONS OF VARENICLINE WITH CONTROL ON NITROSO IMPURITIES
In an embodiment, the present disclosure pertains to a stable formulation of a primary, secondary, and/or tertiary amino group containing composition that prevents or reduces formation of a nitroso impurity until the end of stated expiration or longer, or a method of making the stable formulation of a primary, secondary, and/or tertiary amino group containing composition. In some embodiments, the composition includes a drug having a primary, secondary, and/or tertiary amino group and a pharmaceutical excipient. In some embodiments, the pharmaceutical excipient is at least one of a protective pharmaceutical excipient or a non-protective pharmaceutical excipient. In some embodiments, the composition includes an antioxidant. In some embodiments, the composition includes a chelating agent.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
48.
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM
THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventeur(s)
Song, Xiaotong
Wang, Ruoning
Sarkar, Abhijit
Hu, Yue
Abrégé
The present application provides methods and compositions for treating cancers using a CAR T cell therapy platform. Also provided are methods and use of the CAR T cells for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.
A system for drilling a well includes one of a measure while drilling system or a rotary steerable system and a system on chip for use with a downhole tool of the one of a measure while drilling system or a rotary steerable system. The system on chip includes a processor and memory operable to acquire, process, and execute advanced artificial intelligent agents to identify, correct, and optimize well drilling operations down hole.
E21B 44/00 - Systèmes de commande automatique spécialement adaptés aux opérations de forage, c. à d. systèmes à fonctionnement autonome ayant pour rôle d'exécuter ou de modifier une opération de forage sans l'intervention d'un opérateur humain, p.ex. systèmes de ; Systèmes spécialement adaptés à la surveillance de plusieurs variables ou conditions de forage
G05B 13/04 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
E21B 47/12 - Moyens pour la transmission de signaux de mesure ou signaux de commande du puits vers la surface, ou de la surface vers le puits, p.ex. pour la diagraphie pendant le forage
E21B 47/13 - Moyens pour la transmission de signaux de mesure ou signaux de commande du puits vers la surface, ou de la surface vers le puits, p.ex. pour la diagraphie pendant le forage par énergie électromagnétique, p.ex. gammes de fréquence radio
Brucella melitensisBrucella melitensis Brucella melitensis 16M vjbR vjbRBrucella melitensisBrucella melitensis for treatment of a patient are also provided, including wherein the patient is in need of treatment for cancer, an autoimmune disorder, and/or an inflammatory disorder.
The present disclosure provides methods of treating produce, said method comprising the step of contacting the produce with a ferrate solution. According to the present disclosure, the described methods can prolong shelf life of the produce, disinfect the produce, and/or decontaminate the produce. Advantageously, methods of the present disclosure can be used in a multitude of settings, including agriculture fields, processing facilities, and stores such as grocery stores and supermarkets to improve food supply of produce and prevent illness outbreaks.
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
A01N 25/30 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles caractérisés par les agents tensio-actifs
A23L 5/00 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux
anthracisanthracis Sterne strain 34F2 spores suspended in alginate in an amount sufficient to protect an animal or human from a lethal dose of anthrax.
In an embodiment, the present disclosure pertains to a medical device. In some embodiments, the medical device includes a first compartmentalized microfluidic channel flanked by two microchannels and a second compartmentalized microfluidic channel. In some embodiments, the first and second compartmentalized microfluidic channels are situated vertically one to another. In some embodiments, the medical device further includes a porous membrane situated between the first and second compartmentalized microfluidic channels. In another embodiment, the present disclosure pertains to an organ-on-chip. In some embodiments, the organ-on-chip includes a top portion having three parallel microchannels. In some embodiments, the three parallel microchannels are separated by micropillars. In some embodiments, the organ-on-chip further includes a bottom portion having a fourth microchannel and a membrane between the top portion and the bottom portion.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/04 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'introduction de gaz
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
Described herein are coating compositions and methods of treating fruits and vegetables to resemble the visual appearance of a natural wax bloom on the surface of the fruit or vegetable. The coating composition including a coating agent. The method including applying a coating composition to a surface of the fruit or vegetable, and drying the coating composition on the surface of the fruit or vegetable.
A23B 7/00 - Conservation ou mûrissement chimique des fruits ou des légumes
A23B 7/16 - Recouvrement à l'aide d'une couche protectrice; Compositions ou appareils à cet effet
A23L 3/34 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires par traitement au moyen de produits chimiques
A23B 7/153 - Conservation ou mûrissement à l'aide de produits chimiques non couverts par les groupes ou sous forme de liquides ou de solides
A23L 3/00 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires
55.
METHODS OF PROCESSING ADULT NEURAL CELLS FROM MAMMALS AND ASSAYS THEREOF
The present disclosure provides method of processing neural cells comprising extracting one or more brain components from an animal, dissociating cells from the brain components to form a brain cell composition, purifying the neural cells from the brain cell composition, and culturing the neural cells. Further, the present disclosure provides in vitro assays and related kits utilizing the neural cells, for example in use to screen compounds or therapeutics for neurological diseases or disorders.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
56.
TREATMENT FOR DOWN SYNDROME-RELATED ACCELERATED AGING
222S-reducing ef fective amount of hydrophilic polymer-substituted oxidi zed carbon nanoparticles ( OCNPs ) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subj ect. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
57.
SYSTEMS AND METHODS FOR DETERMINING CONSTITUTIVE PARAMETERS OF SUBJECT MATERIALS
A method for determining constitutive parameters of a subject material includes collecting a force sensor output from a force sensor unit for measuring reactive forces applied to a deformation tool from a subject material travelling in a predefined direction relative to the deformation tool, collecting an image sequence output from a camera unit depicting a deformation zone formed between the deformation tool and the subject material as the subject material is plastically deformed by the deformation tool, and estimating a constitutive parameter of the subject material based on the force sensor output and the image sequence output.
G01N 3/06 - Adaptations particulières des moyens d'indication ou d'enregistrement
G01N 3/42 - Recherche de la dureté ou de la dureté au rebondissement en effectuant des empreintes sous une charge permanente par des dispositifs de pénétration, p.ex. sphère, pyramide
G01N 3/58 - Recherche de l'usinabilité par outils de coupe; Recherche de l'aptitude à la coupe des outils
58.
SELECTIVE SMALL MOLECULE AGONISTS AND PARTIAL AGONISTS OF TRK RECEPTORS
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as diseases of the eye.
In an embodiment, the present disclosure pertains to a composition having a cation and an anion. In some embodiments, a base is incorporated into the anion, and the cation and the anion form a bifunctional catalyst. In some embodiments, the cation is a chiral cobalt(III) species, and a nitrogenous Brpnsted base is incorporated into counter anions of the chiral cobalt(III) species cation. In some embodiments, the bifunctional catalyst is a tricationic cobalt(III) hydrogen bond donor catalyst, and a nitrogenous Brpnsted base is incorporated into counter anions of the tricationic cobalt(III) hydrogen bond donor catalyst. In another aspect, the present disclosure pertains to a bifuntional catalyst having a smart anion with a cationic metal species. In some embodiments, the smart anion performs a specific role in a chemical reaction without the inclusion of additional external components to accomplish a same specific role in the chemical reaction.
B01J 27/18 - Phosphore; Ses composés contenant de l'oxygène avec des métaux
B01J 31/18 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination contenant de l'azote, du phosphore, de l'arsenic ou de l'antimoine
The present disclosure provides pharmaceutical formulations comprising i) a support frame, ii) one or more bioadhesive materials, iii) a first active ingredient, and iv) a second active ingredient. The disclosure also provides methods of treating a subject using the pharmaceutical formulations for various disease states and processes for making the pharmaceutical formulation.
Technologies for multimodal sensing include a wearable device having a flexible substrate and at least one multimodal sensor coupled to the flexible substrate. The multimodal sensor includes a photoplethysmography sensor and a bioimpedance sensor. The wearable device may include context sensors such as an accelerometer, a gyroscope, a temperature sensor, or a pressure sensor. The multimodal sensor may include an integrated pressure sensor. A processor of the wearable device is configured to receive sensor data from the photoplethysmography sensor and the bioimpedance sensor of the multimodal sensor that is indicative of a pulse curve of a user. The processor is further configured to correct the sensor data based on data received from the context sensors and to determine blood pressure data based on the corrected sensor data. The processor may be configured to store the blood pressure data or to transmit the blood pressure data to a remote computing device.
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
A61B 5/257 - Moyens adhésifs, p.ex. garnitures ou bandes adhésives
62.
A PLATFORM FOR THE FAST, LABEL-FREE, AUTOMATED EVALUATION OF STERILITY AND BIOBURDEN
In an embodiment, the present disclosure pertains to a method for evaluation of sterility in a solution using impedance sensing. In another embodiment, the present disclosure pertains to a method for evaluation of bioburden in a solution. In a further embodiment, the present disclosure pertains to various devices for evaluation of sterility or bioburden.
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
63.
SMALL MOLECULE ANTAGONISTS AND AGONISTS OF ARTHROPOD KININ RECEPTORS FOR PEST CONTROL
Applicants have developed novel methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection and identifying kinin receptor agonists and antagonists. Novel compositions include one or more active agents of small molecules antagonists or agonists of arthropod kinin receptor. Methods of preventing disease development and infestation by arthropods are disclosed as well as methods of making, using, and producing such compositions.
A61K 31/38 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle
C07D 335/04 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome de soufre comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
Described herein are compounds and methods for the treatment of coronavirus infection. The compounds can function as an inhibitor of the main protease (Mpro) of coronaviruses. The compounds can include diphenylmethyl piperazine derivatives, diphenylmethyl piperidine derivatives, diphenylmethylidene piperidine derivatives, tricyclo[9.4.0.03,8] pentadeca-1(11),3(8),4,6,12,14-hexaen derivatives, tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen derivatives, 6,11-dihydrobenzo[c][1]benzoxepin derivatives, 6,11-dihydrobenzo[c][1]benzothiepin derivatives, 5,5-dioxo-6,11-dihydrobenzo[c][1]benzothiepin derivatives, and 6-oxo-5,11-dihydrobenzo[c][1] benzazepin derivatives, as well as pharmaceutically acceptable salts, hydrates, and prodrugs thereof.
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/46 - Aza-8-bicyclo[3.2.1]octane; Ses dérivés, p.ex. atropine, cocaïne
65.
INTRACELLULAR TARGETED NANOCARRIERS: TOWARDS CONTROLLED DRUG DELIVERY FOR NONINVASIVE NEUROREGENERATION TREATMENT
In an embodiment, the present disclosure pertains to a nanocarrier having a shell and a core disposed within the shell. In some embodiments, the shell includes a functionalized surface. In an additional embodiment, the present disclosure pertains to a method of drug delivery. In general, the method includes administering a nanocarrier to a subject, targeting, by the nanocarrier, an area in the subject, and releasing a composition having the drug to the area. In some embodiments, the nanocarrier has a shell and a core disposed within the shell. In some embodiments, the shell includes a functionalized surface.
In an embodiment, the present disclosure pertains to a flame-retardant composite composed of a polymer, an intumescent flame retardant (IFR), and a metal-organic framework (MOF). In some embodiments, the MOF is a zeolitic imidazolate framework (ZIF). In some embodiments, the MOF is a bimetallic MOF. In some embodiments, the bimetallic MOF is a bimetal ZIF. In an additional embodiment, the present disclosure pertains to a flame-retardant composite composed of a polymer that can include, without limitation, polypropylene, polyethylene, high- density polyethylene, low-density polyethylene, polystyrene, polyvinyl chloride, poly(methyl methacrylate), a polyolefin, and combinations thereof, an IFR, and a ZIF.
B01J 31/16 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination
C01B 39/04 - Zéolites aluminosilicates cristallines; Leurs composés isomorphes; Leur préparation directe; Leur préparation à partir d'un mélange réactionnel contenant une zéolite cristalline d'un autre type, ou à partir de réactants préformés; Leur post-traitement utilisant au moins un agent structurant organique, p.ex. un composé d'ammonium quaternaire ionique ou un composé aminé
A system for providing tactile feedback to a user includes a device comprising a touch surface to be touched by the user, one or more thermal elements distributed across the touch surface of the device and configured to heat the touch surface and thereby modulate the friction between the user's skin and the touch surface, and a controller connected to the one or more thermal elements and configured to control the operation of the one or more thermal elements to provide a plurality of predefined temperature distributions across the touch surface.
The present disclosure provides compositions comprising novel mass tags. The disclosure also provides methods utilizing mass tags, including methods of quantifying one or more individual lipids from a composition of lipids, methods of identifying a double bond position of an individual lipid, methods of identifying a biological correlation of an individual lipid, and methods of preparing a lipid derivative.
Aspects of the disclosure relate to a robot. The robot includes a body and a wheel assembly coupled to the body. The wheel assembly includes a central hub and a central gear coupled to the central hub. A plurality of legs are coupled to the central hub. The plurality of legs are operatively coupled to the central gear such that the central gear drives the plurality of legs between a closed position and an open position. A motor is coupled to the body and coupled to the wheel. A suspension system is coupled to the wheel assembly. An autonomous guidance system is coupled to the motor.
A61G 5/06 - Fauteuils ou moyens de transport personnels spécialement adaptés pour des personnes handicapées, p.ex. fauteuils roulants avec dispositions pour franchir les obstacles, p.ex. pour monter les escaliers
B60B 15/06 - Roues à crampons avec crampons à pivots
B60B 15/10 - Roues à crampons avec crampons réglables radialement; Mécanismes de commande à cet effet
B60B 15/16 - Roues à crampons avec crampons réglables radialement; Mécanismes de commande à cet effet comportant une transmission, p.ex. pignons dentés attaquant des arbres filetés fixés aux crampons
B62D 51/06 - Tracteurs du type à essieu unique, accompagnés à pied
B62D 57/00 - Véhicules caractérisés par des moyens de propulsion ou de prise avec le sol autres que les roues ou les chenilles, seuls ou en complément aux roues ou aux chenilles
70.
METHOD FOR DETECTING CORROSION SEVERITY OF A METALLIC SURFACE ON A PIPELINE
Provided herein are non-invasive and non-destructive methods for classifying the type of external corrosion defect and the severity thereof in the cathodic protection system on a buried pipeline. Mathematical tools and algorithms are utilized to classify the type and the severity of the corrosion defect.
G01N 17/00 - Recherche de la résistance des matériaux aux intempéries, à la corrosion ou à la lumière
G01N 17/02 - Systèmes de mesure électro-chimique de l'action due aux intempéries, de la corrosion ou de la protection contre la corrosion
G01N 19/08 - Détection de la présence de criques ou d'irrégularités
G01N 27/26 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en utilisant l'électrolyse ou l'électrophorèse
The present disclosure provides methods for producing Phyla dulcis plants and plant parts that are substantially camphor-free and also have an increased level of hernandulcin. Phyla dulcis plants and plant parts, as well as compositions comprising the same, are also provided herein. The present disclosure provides methods that utilize the regulation of the terpenoid biochemical pathways of P. dulcis as opposed to previous methods that depend on chemical synthesis or genetic, enzyme, microbial, and plant tissue engineering.
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
A01N 25/32 - Ingrédient réduisant l'effet nocif des substances actives vis-à-vis d'organismes autres que les animaux nuisibles, p.ex. réducteurs de toxicité, compositions autodestructrices
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Meek, Thomas D.
Li, Linfeng
Tseng, Chien-Te Kent
Drelich, Aleksandra
Abrégé
Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.
A catheter control system may include a containment structure, a sensor coupled to the containment structure, and a plurality of actuators coupled to the containment structure. The containment structure may define a lumen configured to allow a fluid to flow therethrough, and a plurality of openings in fluid communication with the lumen. The sensor may be configured to detect a current position and/or orientation of the containment structure. Each of the actuators may be associated with at least one respective opening of the plurality of openings and configured to regulate fluid flow through the at least one respective opening.
In an embodiment, the present disclosure pertains to an electrode having a first layer and a second layer. In some embodiments, the first layer includes a conductive polymer. In some embodiments, the second layer is positioned above the first layer. In some embodiments, the second layer includes an inorganic material that forms a conductive network on the first layer. In an additional embodiment, the present disclosure pertains to a method of making an electrode. In general, the method providing a mold with a desired indented pattern, pouring a solution including a conductive polymer into the indented pattern to form a first layer, and pouring a solution including an inorganic material onto the first layer to form a second layer. In some embodiments, the inorganic material forms a conductive network on the first layer.
A61B 5/268 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet caractérisées par les matériaux des électrodes contenant des polymères conducteurs, p.ex. des polymères PEDOT:PSS
A61B 5/265 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet caractérisées par les matériaux des électrodes contenant de l’argent ou du chlorure d’argent
H01L 51/10 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés au redressement, à l'amplification, à la génération d'oscillations ou à la commutation et ayant au moins une barrière de potentiel ou une barrière de surface; Condensateurs ou résistances à l'état solide, ayant au moins une barrière de potentiel ou une barrière de surface - Détails des dispositifs
H01L 51/52 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED) - Détails des dispositifs
H01L 51/44 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement - Détails des dispositifs
A breath capture and analysis system includes a breath inlet for capturing a user's breath. The breath is drawn into the system and retained for analysis. The system includes a membrane that allows volatile organic compounds contained in the breath to pass therethrough. The volatile organic compounds pass into a vacuum chamber that includes a residual gas analyzer that is configured to analyze the volatile organic compounds. The analyzed breath is then vacated from the system.
A61B 5/097 - Dispositifs pour faciliter la collecte du gaz respiré ou pour le diriger vers ou à travers des dispositions de mesure
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
B01D 53/02 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse
B01D 53/04 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
76.
SYSTEMS AND METHODS FOR EVALUATION OF STRUCTURE AND PROPERTY OF POLYNUCLEOTIDES
Provided here are neural network-based methods and systems that process nucleic acid sequences to identify, characterize, and interpret specific properties, like characterization of promoters of gene sequences, identification of viral genomes, and stability of the nucleic acids. The neural network models can be trained in supervised, unsupervised, and semi-supervised environments.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
US HYBRID CORPORATION (USA)
Inventeur(s)
Toliyat, Hamid A.
Praslicka, Bryton
Zamarron, Daniel
Gardner, Matthew C.
Johnson, Matthew C.
Goodarzi, Abas
Bauk, Enzo
Nguyen, Alex
Hasanpour, Shima
Abrégé
Aspects of the disclosure relate to a cycloidal magnetic gear. The cycloidal magnetic gear includes an outer rotor. A plurality of magnetic pole pairs is disposed on an inner circumference of the outer rotor. A first, second, and third inner rotor is disposed within the outer rotor. The first, second, and third inner rotors includes a magnetic pole pairs disposed on an outer circumference thereof. The first inner rotor and the third inner rotor have a thickness of approximately half the thickness of the second inner rotor. The first inner rotor, the second inner rotor, and the third inner rotor balance moments acting on a drive shaft.
F16H 1/28 - Transmissions à engrenages pour transmettre un mouvement rotatif avec engrenages à mouvement orbital
F16H 1/34 - Transmissions à engrenages pour transmettre un mouvement rotatif avec engrenages à mouvement orbital comportant des engrenages ayant essentiellement des éléments engrenants autres que des dentures à développante ou cycloïdales
A method of removing pollutants from flue gas includes cooling the flue gas to remove condensed water. The flue gas is then compressed and dehydrated. The dehydrated flue gas is chilled to separate pollutants.
F25J 3/02 - Procédés ou appareils pour séparer les constituants des mélanges gazeux impliquant l'emploi d'une liquéfaction ou d'une solidification par rectification, c. à d. par échange continuel de chaleur et de matière entre un courant de vapeur et un courant de liquide
B01D 53/04 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
B01D 53/28 - Emploi de substances spécifiées comme agents desséchants
79.
DIRECT CARDIAC COMPRESSION DEVICE WITH IMPROVED DURABILITY
The present invention provides a direct cardiac compression device comprising one or more passive chambers that taper from an aperture to an apex; one or more inflatable active pockets individually independently inflatable, wherein each of the one or more inflatable active pockets is connected to the one or more passive chambers at least partially from the aperture to the apex and wherein the each of the one or more inflatable active pockets does not tension the adjacent one or more inflatable active pockets upon inflation; and a frame in contact with the one or more active chambers to at least partially surround the one or more active pockets.
A61M 1/12 - Pompes pour le sang; Cœurs artificiels; Dispositifs pour aider mécaniquement la circulation, p.ex. pompes à ballon intra-aortique implantables dans le corps
A method of characterizing brain activity includes receiving an electroencephalogram (EEG) output. In addition, the method includes determining a mathematical model of a brain using the EEG output, wherein the mathematical model comprises a plurality of ordinary differential equations (ODEs) that are determined based on the EEG output. Further, the method includes characterizing brain activity of a subject using the mathematical model.
A61B 5/291 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/316 - Modalités, c. à d. méthodes diagnostiques spécifiques
A61B 5/369 - Modalités, c. à d. méthodes diagnostiques spécifiques Électroencéphalographie [EEG]
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p.ex. détection des ondes delta, thêta, alpha, bêta ou gamma
81.
POLYMER/PHASE CHANGE MATERIAL COMPOSITE INK FOR THREE-DIMENSIONAL PRINTING BY DIRECT INK WRITING
In an embodiment, the present disclosure pertains to an ink composition. In some embodiments, the ink composition includes particles composed of a phase change material (PCM) and a resin. In an additional embodiment, the present disclosure pertains to a method of making an ink composition. In general, the method includes forming PCM beads from a PCM and loading a resin with the PCM beads. In a further embodiment, the present disclosure pertains to a method for forming a material or structure. In general, the method includes printing a composite ink on a substrate. In some embodiments, the composite ink includes particles composed of a PCM and a resin. In some embodiments, the method further includes curing the resin to thereby form the material or stmcture and imparting thermal regulation, by the composite ink, onto the material or structure.
B41J 2/015 - Machines à écrire ou mécanismes d'impression sélective caractérisés par le procédé d'impression ou de marquage pour lequel ils sont conçus caractérisés par la mise en contact sélective d'un liquide ou de particules avec un matériau d'impression à jet d'encre caractérisés par le procédé de formation du jet
B41M 5/00 - Procédés de reproduction ou méthodes de reproduction ou de marquage; Matériaux en feuilles utilisés à cet effet
C07C 69/16 - Esters d'acide acétique de composés dihydroxylés
82.
THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Chan, Stephen Yu-Wah
Kim, Seungchan
Abrégé
Disclosed are pathogenic mechanisms in pulmonary hypertension and molecular inhibitors of the same. Particularly, GSTP1 (glutathione S-transferase P1) have been demonstrated as having a role in regulating the endothelial ISCU function in pulmonary hypertension. Accordingly, methods for treating pulmonary hypertension in a subject in need thereof comprising administering a therapeutically effective amount of a pharmaceutical composition that inhibits glutathione S-transferase P (GSTP1) and/or increasing ISCU expression are disclosed. The GSTP1 inhibitor can comprise a piperlongumine analog, such as BRD-K34222889, or a derivative thereof.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A system for producing a product is disclosed. The system includes a production facility for producing a product using a chemical process involving chemical reactions, and an information processing device comprising a computer processor that simulates, using a hybrid model, the chemical reactions in the chemical process that produces the product to obtain a predicted output, wherein the hybrid model is a combination of a first-principles model and a data-driven model, determines, using an observer model, expected concentrations and levels of all substrates for the simulated process, sets derived optimal conditions for the chemical process based on the estimated concentrations and levels of all substrates, and predicts future production results based on a current status of the production facility.
Systems and methods for controlling end-effectors. In some examples, a system includes a finger-tracking system configured for tracking one or more fingers of an operator and controlling movement of the end effector based on tracking the one or more fingers. The system includes a sensor configured for measuring a distance between the end effector and a target object in an environment of the end effector. The system includes a feedback system configured for electrically stimulating at least one of the one or more fingers of the operator with an electrical pulse having a frequency based on the distance between the end effector and the target object.
A conformal dipole winding includes a superconducting tape configured with a geometry that orients a face of the superconducting tape to be parallel to a local magnetic field produced by the winding along a length of the superconducting tape. The superconducting tape forms a tape-stack cable formed from a stack of a plurality of the superconducting tapes. A face of each of the superconducting tapes is oriented parallel to the local magnetic field and is in face-face contact with adjacent superconducting tapes.
H01B 12/02 - Conducteurs, câbles ou lignes de transmission supraconducteurs ou hyperconducteurs caractérisés par leurs formes
H01B 12/06 - Conducteurs, câbles ou lignes de transmission supraconducteurs ou hyperconducteurs caractérisés par leurs formes à couches ou fils déposés sur des supports ou des noyaux
H01F 6/06 - Bobines, p.ex. dispositions pour l'enroulement, l'isolation, les enveloppes ou les bornes des bobines
86.
X-RAY AND MRI VISIBLE SHAPE MEMORY POLYMER BIOPSY SEALING DEVICE
An embodiment includes a shape memory polymer (SMP) foam with visibility under both X-ray and magnetic resonance imaging (MRI) modalities. Dual modality visibility is achieved by chemically incorporating monomers with X-ray visible iodine-motifs and MRI visible monomers with gadolinium content. This material platform has the potential to be used in a variety of medical devices.
A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p.ex. les vaisseaux sanguins ou le cordon ombilical
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets
The present disclosure is directed to a new and improved separation process that isolates individual minerals from brines containing a mixture of minerals. The brines may be derived from seawater, brackish water, oilfield brines, solution mining, mine run-off, and other sources. Typically, the minerals are recovered as chlorides using a variety of processing steps including evaporation, centrifugation, elutriation, filtration, electrocogulation, crystallization, adsorption, and chromatography.
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Meek, Thomas D.
Tseng, Chien-Te
Drelich, Aleksandra
Mellott, Drake M.
Abrégé
Provided herein are pharmaceutical compositions including compounds having Formula I (I) in an effective amount to inhibit non-viral cysteine protease (e.g., mammalian cysteine protease, such as human cathepsin L), as well as methods of using thereof.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
A61P 31/14 - Antiviraux pour le traitement des virus ARN
89.
REFERENCE-FEE FOREIGN ACCENT CONVERSION SYSTEM AND METHOD
Provided herein is a reference-free foreign accent conversion (FAC) computer system and methods for training models, utilizing a library of algorithms, to directly transform utterances from a foreign, non-native speaker (L2) or second language (L2) speaker to have the accent of a native (L1) speaker. The models in the reference-free FAC computer system are a speech-independent acoustic model to extract speaker independent speech embeddings from an L1 speaker utterance and/or the L2 speaker, a speech synthesizer to generate L1 speaker reference-based golden-speaker utterances and a pronunciation correction model to generate a L2 speaker reference-free golden speaker utterances.
Methods, systems, and computer readable media for thermal load management of a collection of power consumers managed by an electric power aggregator. In some examples, a system includes a scheduling subsystem, implemented on one or more processors, configured for determining a plurality of cooling or heating control schedules for the collection of power consumers by forecasting one or more wholesale electricity price peaks. The system includes a control system implemented on one or more processors. The control system is configured for carrying out the cooling or heating control schedules at the individual consumer-level. The control system is configured for guaranteeing, for each power consumer of the collection of power consumers, a comfort constraint specified by a bilevel thermostat for the power consumer, wherein the comfort constraint comprises a lower bound temperature and an upper bound temperature that the power consumer is willing to tolerate.
G06Q 50/06 - Fourniture d'électricité, de gaz ou d'eau
G05B 15/02 - Systèmes commandés par un calculateur électriques
H02J 3/00 - Circuits pour réseaux principaux ou de distribution, à courant alternatif
H02J 3/14 - Circuits pour réseaux principaux ou de distribution, à courant alternatif pour règler la tension dans des réseaux à courant alternatif par changement d'une caractéristique de la charge du réseau par interruption, ou mise en circuit, des charges du réseau, p.ex. charge équilibrée progressivement
A surge gate for blocking a surge of water includes a sleeve disposed below a waterline of the water, wherein the sleeve has an open upper end and a closed lower end, and a piston slidably disposed in the sleeve, wherein the piston is configured to rise vertically within the sleeve along a vertical axis between a first position with an upper end of the piston positioned below the waterline, and a second position with the upper end of the piston positioned above the waterline.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
THE TEXAS A&M UNIVERSITY SYSTEM (USA)
Inventeur(s)
Cornelius, Lisa, K.
Jinadatha, Chetan
Abrégé
A mobile personal protective equipment (PPE) station can comprise a frame that is configured to be movable on a floor surface and a shield that is coupled to the frame. The shield can comprise a front wall that extends along a first horizontal axis. The front wall can define a pair of arm holes. At least a portion of the front wall can be transparent.
B08B 15/00 - Précautions prises pour empêcher les crasses ou les fumées de s'échapper de la zone où elles sont produites; Ramassage ou enlèvement des crasses ou fumées de cette zone
93.
BONDING DISSIMILAR MATERIALS USING RADIO FREQUENCY WAVE CURING
A method is provided for bonding substrates having dissimilar coefficients of thermal expansion, using a thermoset adhesive. The method involves a pre-cure step using radio-frequency energy, followed by a heat-curing step.
C09J 5/06 - Procédés de collage en général; Procédés de collage non prévus ailleurs, p.ex. relatifs aux amorces comprenant un chauffage de l'adhésif appliqué
C09J 11/04 - Additifs non macromoléculaires inorganiques
Systems and methods are disclosed for identifying subsurface features as a function of position in a subsurface volume of interest. Exemplary implementations may include obtaining target subsurface data; obtaining a conditioned subsurface feature model; applying the conditioned subsurface feature model to the target subsurface data, which may include generating convoluted target subsurface data by convoluting the target subsurface data; generating target subsurface feature map layers by applying filters to the convoluted target subsurface data; detecting potential target subsurface features in the target subsurface feature map layers; masking the target subsurface features; and estimating target subsurface feature data by linking the masked subsurface features to the target subsurface feature data.
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
The current invention provides vector constructs that are pre-programmed to self-terminate or self-remove at a predetermined time and methods of making the same. The present invention further provides methods for creating organisms containing these vector constructs. Also provided are various transgenic organisms with the vector constructs, including plants, insects, and mammals.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminée; Leurs dérivés contenant au moins une liaison peptidique anormale
The present invention relates to the discovery of miRNAs which can be isolated from the blood of neonates, especially the umbilical cord and/or placental blood of neonates which have been determined to be biomarkers for neonatal opioid withdrawal syndrome (NOWS). One or more of these biomarkers, often at least three in conjunction may be measured in the blood, preferably the cord or placental blood of neonates suspected of having opioid withdrawal syndrome and compared with a standard wherein the measurement of the one or more biomarkers evidences the presence of opioid syndrome in the neonate whose blood has been measured so that effective measures can be taken to treat, the withdrawal syndrome and inhibit, limit and/or reverse withdrawal syndrome in the neonate shortly after birth. In an embodiment, the cord and/or placental blood of an unborn neonate may be obtained and analyzed for opioid withdrawal syndrome, in an embodiment, one or more biomarkers as identified herein may be utilized to determine the effectiveness of therapy by measuring the biomarker at more than one time during a period of therapy for opioid withdrawal syndrome to determine if the concentration of biomarker has normalized to levels closer to that of a standard.
A multilayer crown includes an outer layer and an inner layer. The outer layer may be formed of a first polymeric material. The inner layer may be formed of a second polymeric material that is different from the first polymeric material. The inner layer may be arranged to contact a tooth so that the inner layer is located between the outer layer and the tooth.
The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating polypeptides. The methods can involve administering serum amyloid P-component to a patient suffering from CALD or cytokine storm.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
100.
THERAPEUTIC CARBON NANOMATERIAL H2S OXIDANTS FOR BIOLOGICAL POLYSULFIDE SYNTHESIS
in vitroin vivoin vivo using endogenously or exogenously released hydrogen sulfide is disclosed. That method comprises contacting cells in need including those under oxidative stress, traumatic brain injury (TBI) and hypoxia, or have an excess of hydrogen sulfide or deficiency of protein persulfidation with oxidized carbon nanoparticulate material in which the particles contain a plurality of carbonyl, hydroxyl and carboxyl substituents. Oxidized carbon nanoparticulate (OCN) material can be prepared from any of a variety of sources of which activated charcoal is preferred. A water-dispersible OCN material is described that does not need added hydrophilic polymers to provide dispersibility for at least 7 days at a concentration of about 1-5 mg/mL. These OCN materials also have a UV absorbance maximum in water of about 220 nm and pass through a 0.22 μm pore PES membrane.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 33/44 - Carbone élémentaire, p.ex. charbon de bois, noir de carbone
brevets
